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29 A high performance liquid chromatography tandem mass spectrometric method was developed 
30 and validated cenicriviroc quantification in human plasma and cerebrospinal fluid. The method 
31 involved precipitation with acetonitrile and injecting supernatants onto the column. Separation 
32 was achieved on an XBridge C18 column with a gradient elution of 0.1% formic acid in water 
33 and acetonitrile. Analyte detection was conducted in positive ion mode using SRM. The m/z 
34 transitions were: CVC (697.3→574.3) and CVC-d7 (704.4→574.3). Calibration curve ranged 
35 from 5-1000 ng/ml for plasma and 0.241-15.0 ng/ml for CSF. The intra and inter day precision 
36 and accuracy were <15% for both plasma and CSF across four different concentrations. 
37 Cenicriviroc recovery from plasma and artificial CSF was >90%. The method was utilised for 




















































































58 Cenicriviroc (CVC) is a novel potent dual antagonist of the chemokine co-receptors 5 and 2 
59 (CCR5/CCR2) and blocks HIV-1 entry (Kramer, Hassounah, Colby-Germinario, Oliveira, 
60 Lefebvre, Mesplede and Wainberg 2015). CVC has been tested in Phase IIb trials, for the 
61 treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis and consistently 
62 demonstrated an improvement in liver fibrosis (Tacke 2018). Cenicriviroc is also expected to 
63 have potent anti-inflammatory activity (Lalezari, Gathe, Brinson, Thompson, Cohen, Dejesus, 
64 Galindez, Ernst, Martin and Palleja 2011). Furthermore, CVC presents a long half-life (~40hrs) 
65 supporting once-daily dosing (Marier, Trinh, Pheng, Palleja and Martin 2011, S. Palleja 2009). 
66 The replication of HIV RNA in the central nervous system (CNS) creates the potential for HIV-
67 associated cognitive impairment. It is postulated that CCR5 antagonists could target HIV RNA 
68 replication in sanctuary sites a method previously shown to have beneficial effects in the CNS 
69 (Garvey, Nelson, Latch, Erlwein, Allsop, Mitchell, Kaye, Watson, Back, Taylor-Robinson and 
70 Winston 2012). This method was developed and validated to assess Cenicriviroc in in plasma 
71 and cerebrospinal fluid (CSF) as part of a Phase II feasibility study, (EudraCT 2015-002955-
72 85), 
73
74 Plasma levels of Cenicriviroc have previously been quantified using liquid chromatography/ 
75 tandem mass spectrometry (LC-MS/MS) (Lefebvre, Gottwald, Lasseter, Chang, Willett, Smith, 
76 Somasunderam and Utay 2016), but the methods have not been published. Also, to our 
77 knowledge, there are no CSF methods published either. We present here a simple tandem mass 
78 spectrometric method for quantification of Cenicriviroc in plasma and in CSF using protein 
79 precipitation extraction and validated in accordance with EMA and FDA guidelines ( 2012,  
80 2018).
81
































































82 Materials and Methods
83
84 Chemicals
85 CVC and CVC-d7 were obtained from Allergan Inc, Irvine, California; methanol and 
86 acetonitrile (LC-MS grade) were obtained from Sigma–Aldrich. Deionized water (HPLC 
87 grade) was obtained from an Elga Option 4 water purifier (Elga LabWater, High Wycombe, 
88 United Kingdom). Further purification to 18.2 MΩ was carried out using a Purelab Classic 
89 UVF (Elga LabWater). Whole blood, collected in K2EDTA, was obtained from healthy drug-
90 free volunteers with Ethics approval from the NHS Health Research Authority. Artificial CSF 
91 was obtained from Harvard Apparatus and Human Serum Albumin from Sigma–Aldrich, UK.
92
93 Equipment
94 The chromatographic system was made up of a variable loop Accela autosampler (temperature, 
95 6°C) and an Accela LC pump (Thermo Fisher Scientific, Hemel Hempstead, United Kingdom). 
96 The analyte and internal standard (IS) were eluted using a reverse-phase C18 XBridge column 
97 (3.5 μm:50 mm × 2.1 mm; Waters UK) with a guard column (at an oven temperature of 40°C. 
98 The mass spectrometer was a triple–quadrupole TSQ Quantum Access (Thermo Fisher 
99 Scientific, UK) with a heated-electrospray ionization source. Tuning, data acquisition and 
100 processing were carried out using TSQ Tune and LC Quan Software (Thermo Fisher Scientific) 
101 respectively.
102
103 Stock solution preparation
104  Methanolic stock solutions (1 mg/mL) were prepared, with working solutions containing (100 
105 µg/mL and 10 µg/mL of CVC) prepared by diluting the stock solution with more methanol. 
106 The internal standard working solutions for plasma (100 ng/mL of CVC-d7) and CSF (10 
107 ng/mL of CVC-d7) were also prepared in methanol.
108
109 For plasma, working calibration sub-stock solutions were prepared from 100µg/mL by diluting 
110 in the appropriate volume of methanol to a final concentration of 50, 12.5 and 0.625 µg/ml. 
111 Working calibration standards were prepared by spiking blank human plasma to yield 12.5, 
112 250, and 1000 ng/mL CVC calibration standard solutions. The working calibration standard 
113 solutions were serially diluted to yield final plasma concentrations of 5.0, 12.5, 50.0, 125.0, 
































































114 250.0, 500.0, 800.0, and 1000.0 ng/mL of CVC. All standards were prepared using calibrated 
115 air-displacement pipettes.
116
117 For CSF, working calibration sub-stock solutions were prepared from 10 µg/mL by diluting in 
118 the appropriate volume of methanol to a final concentration of 0.012, 0.019, 0.049, 0.097, 
119 0.195, 0.433, 0.623 and 0.750 µg/mL. Calibration curves were prepared by spiking the working 
120 calibration sub-stock solution into artificial CSF containing 0.5% human serum albumin, 
121 yielding eight calibration standards (0.241, 0.389, 0.973, 1.947, 3.894, 8.653, 12.45, 
122 15.0ng/mL). Quality Control (QC) samples were prepared from the CVC QC primary stock. 
123 These consisted of High QC (750 ng/mL), Medium QC (150 ng/mL), Low QC (11.3 ng/mL; 
124 3x the lowest calibration standard concentration) and the lower limit of quantification (LLQ; 
125 5.0 ng/mL) for plasma and for CSF (HQC; 12.50, MQC; 2.25, LQC; 0.720 and LLQ; 0.241 
126 ng/mL).
127
128 Non-specific binding of Cenicriviroc in CSF
129 Hydrophobic compounds are often lost due to adsorption onto glass and plastic lab-ware when 
130 in low-protein biological matrices such as urine and CSF (Gu, Deng, Wang, Aubry and Arnold 
131 2010, Ji, Jiang, Livson, Davis, Chu and Weng 2010, P.Nouri 2016). Minimising or resolving 
132 the adsorption loss is often achieved using a variety of methods including: addition of plasma, 
133 bovine serum albumin or surfactants such as Tween 20, sodium dodecylbenzenesulfonate or 3-
134 [3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)(Chen, Bajpai, Mollova 
135 and Leung 2009, Silvester and Zang 2012, Xu, Du, Rose, Fu, Woolf and Musson 2005) 
136 There was a significant loss of Cenicriviroc observed in aCSF, with increased variability from 
137 the nominal concentrations (%Bias) and within replicates. This loss was observed across the 
138 entire calibration range from 0.24 ng/mL to 15 ng/mL. This was due to non-specific binding of 
139 Cenicriviroc to the glass tubes when serial dilutions were performed in CSF. Separate 
140 preparation of individual calibrant levels in pure methanol, to eliminate the serial dilution step, 
141 followed by direct spiking into blank CSF did not reduce this effect. 
142 The addition of human serum albumin at different concentrations (0.01-1%) was evaluated as 
143 a method of preventing the non-specific binding of CVC in CSF samples. Based on the results, 
144 artificial CSF was pre-treated with 0.5% human serum albumin before the preparation of 
145 calibration standards and quality control samples. (Table 1). 
































































146 The addition of 0.5% human serum albumin (w/v) greatly improved analyte response and 





152 CVC was extracted from both plasma and CSF by protein precipitation using acetonitrile. 
153 Standards, QCs, blank and study samples (100µl) were aliquoted into 5mL glass test tubes, to 
154 each of which internal standard working solution (CVC-d7; 20µl) was added. 100µl of 0.1% 
155 formic acid solution in water was also added to the mixture followed by precipitation with 
156 500µl of acetonitrile. Samples were vortexed for approximately 1 minute and then centrifuged 
157 (4000 rpm, 4°C, 5 minutes) and the supernatant transferred to autosampler vials. The vials were 
158 loaded onto autosampler trays and 5μL injected into the LC-MS/MS system for analysis.
159
160  LC-MS/MS Procedure
161 Chromatographic separation was achieved using a Waters C18 XBridge column (3.5μm: 
162 50 mm × 2.1 mm) and 5mM ammonium acetate solution with 0.1% formic acid (mobile phase 
163 A) and acetonitrile (mobile phase B). Cenicriviroc was eluted from the column using a gradient 
164 method at a flow rate of 400µl/min. Mobile phase gradient started with 80% mobile phase A, 
165 which was held for 0.3 minutes then increasing in organic content to 85% mobile phase B in 
166 0.8 minutes. This was maintained over up to 2.5 minutes followed by increasing the organic 
167 content to 100% over for 13.5 minutes and back to the initial conditions for reconditioning with 
168 a total run time of 5 minutes.
169
170 The electrospray ionisation (ESI) mass spectrometer (MS) was operated in positive ion mode 
171 using selective reaction monitoring (SRM). These were the MS settings:-  electrospray voltage, 
172 5.0kV; capillary temperature, 270°C; vaporiser temperature, 350°C; sheath and auxiliary gas 
173 pressures, 50 and 20 arbitrary units respectively. The collision gas Argon, was delivered at a 
174 pressure of 1.5mTorr with collision energy set to 20 and tube lens set to 50. The m/z transitions 
175 for CVC was 697.3→574.3 and CVC-d7, 704.4→574.3 and. The scan width was set at 0.01 
176 and the scan time at 0.1 seconds. The peak width settings for Q1 and Q3 were set at unit 
177 resolution (0.7).
































































178 Initial chromatographic optimisation was with a conventional C18 column using acetonitrile 
179 and formic acid as additives at low concentrations in mobile phase but this resulted in peak 
180 tailing. Altering the pH and buffers at to different concentrations did not improve the peak 
181 shape. Cenicriviroc has is a strong weak polyprotic basice pKa value (pKa=6.39), making the 
182 molecule prone to secondary interaction with silanes of the column. Changing the column to a 
183 high purity silica type with end-capping was considered, in order improve the peak shape. The 
184 XBridge C18 column is known for its Ethylene Bridged Hybrid (BEH) technology and 
185 advanced end-capping. The previously used mobile phase was not sufficient to get a reasonable 
186 signal and a good peak shape using the XBridge column. However, addition of 5mM 





192 Six different lots of blank human plasma were used in this assessment. Selectivity was 
193 determined at the LLQ, where the precision should be ≤20% and accuracy within 20% of the 
194 nominal concentrations. (n = 6). Also, interference or noise response at the same retention time 
195 of internal standard were deemed acceptable if the % interference was less than 5% of the mean 
196 response of the internal standard areas in 6 LLQ samples.
197
198 Accuracy and Precision
199 Three separate accuracy and precision batches were run consisting of a calibration curve and 
200 LLQ, LQC, MQC and HQC samples in replicates of six. Data from the manufacturers’ 
201 observed Cmax following standard dosing (and adjusted dosing based on interaction with other 
202 ART agents that induce or inhibit hepatic iso-enzymes) served as a guide to setting the 
203 calibration range. 
204  Carryover 
205 The carryover was assessed by injecting blank samples, followed by assay LLQ (5 ng/mL) and 
206 upper limit of quantification (ULQ; 1000 ng/mL) standards, were run in duplicate. This was 
207 followed by 3 blank plasma samples.  The % carryover (in the blank samples after ULQ) was 
































































208 calculated after each subsequent run, and expressed in relation to the assay LLQ;  the % 
209 carryover should not exceed 20% of the LLQ concentration (EMA Bioanalytical method 
210 validation) .
211 Dilution integrity
212 CVC concentrations between 160-180% of the assay ULQ was spiked into plasma, which was 
213 subsequently diluted 1:2 and 1:4 with blank plasma.  The samples were then analysed, with 
214 concentrations from the standard curve (including the appropriate dilution factor), and 
215 compared against the expected nominal concentration.
216 Recovery and Matrix effects
217 The % recovery and matrix effects were determined quantitatively using the methods of 
218 Matuszewski et al (Matuszewski, Constanzer and Chavez-Eng 2003). The % recovery (process 
219 efficiency) was obtained by comparing the peak-area of the analyte at LQC/MQC/HQC 
220 concentrations from extracted plasma samples, to the peak area of analyte spiked at an 
221 equivalent concentration in mobile phase. The % matrix effect compared the peak areas of 
222 CVC spiked into blank plasma extracts with the peak areas of CVC in mobile phase at an 
223 equivalent concentration. 
224 Stability 
225 The stability of Cenicriviroc in plasma  and CSF under different conditions (QC samples; 6 per 
226 level) was assessed after:- heat inactivation at 58oC for 40 minutes; and over 3 freeze-thaw 
227 cycles spanning a period of 3 days.  Bench-top stability was also assessed at room temperature 
228 over 6 hours (n=4, per level); and furthermore, by re-injecting an accepted precision and 
229 accuracy batch (6 QC per level) which had been left in the autosampler at 4oC for 48 hours, 
230 reinjection reproducibility was assessed. 
231
232 Measurement of Cenicriviroc in human plasma and CSF
233 Blood samples for the pharmacokinetic analysis of CVC in a phase II open-label feasibility 
234 study in 7 HIV-positive volunteers were analysed using this method. Of the seven participants, 
235 only four completed all study procedures (EudraCT 2015-002955-85). The study was 
236 conducted at St Mary’s Hospital, Imperial College Healthcare NHS Trust, London, UK, 
237 between March and December 2016. Human ethics approval was obtained (The Brighton and 
































































238 Sussex Research Ethics Committee, UK, reference: 15-LOC-1887). Cenicriviroc was 
239 administered once daily in the morning with food, for 8 weeks. Dose was 150 mg daily when 
240 administered with ART without significant effects on hepatic isoenzymes. This dose was 
241 reduced to 50 mg daily or increased to 300 mg daily when administered alongside ART with 
242 significant inhibition effects (HIV protease inhibitors) or with significant induction effects 
243 (efavirenz) on hepatic isoenzymes, respectively. Blood was drawn at baseline and week 8. 
244 Collected whole blood was immediately placed on ice until centrifugation to separate plasma 
245 from the blood cells. Plasma was aliquoted and stored at −40 °C until analysis. The subjects 
246 had their CSF collected by lumbar puncture. The CSF samples were aliquoted and immediately 





252  There was minimal background interference (<10% of the signal response at the LLQ for 
253 CVC) and suitable selectivity in all six plasma batches chosen. 
254 Accuracy and Precision
255 The accuracy and precision (both inter- and intra-assay) values at the assay LLQ fell within the 




260 The mean % carryover (n=3) observed in the first extracted blank sample following injection 
261 of an ULQ sample (1000 ng/mL) was 0.13% for CVC. This represented 26.9% of the assay 
262 LLQ that, upon injection of the second blank plasma sample, reduced to 0.03% for CVC which 
263 is equivalent to 5.8% of the assay LLQ. 
264 Dilution integrity
































































265 Samples diluted by a factor of 2 and 4 times showed calculated concentrations within ± 15% 
266 of the nominal values. The %CV for the diluted samples was <10% for Cenicriviroc.
267
268 Recovery and Matrix effects  
269 Matrix effects (ME), Recovery Efficiency (RE), and Process Efficiency (PE) were studied for 
270 both plasma and CSF matrices each at three different concentrations. Overall recovery is 




275 Stability data are presented in Table 4. Samples were stable for up to 48 hours following re-
276 injection within the LC-MS/MS autosampler (4oC) with concentrations within ±15% of the 
277 respective nominal values. Cenicriviroc was also stable after heat treatment and through 3 
278 freeze-thaw cycles (n=4).  Furthermore, when left on the bench at room temperature, the 




283 Application of method to clinical pharmacokinetic study
284 All subjects had plasma and cerebrospinal fluid cenicriviroc concentrations below the LLQ at 
285 baseline. At week eight, peak plasma cenicriviroc concentrations was detectable in all four 
286 subjects, but detectable in the cerebrospinal fluid in only two subjects (mean 0.82 and 0.40 
287 ng/mL respectively), and below the LLQ in the other two subjects. Mean cerebrospinal fluid: 
288 plasma cenicriviroc concentration ratio was no more than 0.18% (95% CI of the upper estimate 
289 0.09% – 0.28%).(Alagaratnam, Dilly-Penchala, Challenger, Else, Legg, Petersen, Jones, 









































































299 In this study, a sensitive, selective, accurate and robust LC–MS/MS method was developed 
300 and validated to quantify cenicriviroc in human plasma and CSF. This, to the best of our 
301 knowledge, is the first method quantifying cenicriviroc concentrations in CSF. 
302 Furthermore, this assay will provide a greater understanding of CVC pharmacokinetics across 
303 different individuals under different treatment scenarios. The incurred sample analysis met the 
304 acceptance criteria and as previously mentioned, the method has been used to study the 
305 pharmacokinetics of cenicriviroc in plasma and CSF as part of a clinical trials.
306
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313 Figure 1. Chromatograms of cenicriviroc and cenicriviroc-d7 in CSF in a) Blank aCSF sample   b) 
314 Spiked with 0.24ng/ml (LOQ)   c) Patient sample at week 8   d) Internal standard CVC-d7
315
316 Figure 2. Chromatograms of cenicriviroc and cenicriviroc-d7 in Plasma e) Chromatogram of Blank 
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Table 1. Variability from nominal concentrations (%Bias) observed before and after pre-treatment with 
human serum albumin (0.5% w/v)
Untreated artificial CSF Artificial CSF pre-treatedwith 0.5% serum albumin human Nominal 
Concentration







0.309 28.2 0.200 -17.00.241
0.277 14.9 0.280 16.0
0.336 -13.6 0.416 7.0
0.389
0.347 -10.8 0.393 1.1
0.453 -53.4 0.898 -7.70.973
0.548 -43.7 0.922 -5.2
1.292 -33.6 1.714 -12.0
1.947
0.809 -58.4 1.821 -6.5
6.402 64.4 4.098 5.33.894
4.681 20.2 3.699 -5.0
9.673 11.8 8.118 -6.2
8.653
11.139 28.7 8.317 -3.9
14.520 16.6 15.043 20.812.450
16.623 33.5 14.053 12.9
14.326 -4.5 16.535 10.2
15.000
14.931 -0.5 15.884 5.9
































































 Table 2. Accuracy & Precision (inter- and intra-day) for CVC in Plasma & CSF
LLQ (5 ng/mL) LQC (11.3 ng/mL) MQC (150 ng/mL) HQC (750ng/mL)Plasma
Mean SD %CV %Bias Mean SD %CV %Bias Mean SD %CV %Bias Mean SD %CV %Bias
Inter-day 5.23 0.54 10.26 4.59 11.90 0.82 6.90 5.33 159.52 12.96 8.12 6.35 792.53 54.68 6.90 5.67
Intra-day 5.46 0.305 5.59 9.21 12.38 0.51 4.15 9.58 165.01 4.66 2.83 10.00 789.03 33.90 4.30 5.20
LLQ (0.241 ng/mL) LQC (0.720 ng/mL) MQC (2.25 ng/mL) HQC (12.5 ng/mL)CSF
Mean SD %CV %Bias Mean SD %CV %Bias Mean SD %CV %Bias Mean SD %CV %Bias
Inter-day 0.26 0.04 13.70 9.42 0.72 0.072 10.05 -0.59 2.36 0.32 13.51 3.62 12.48 1.78 14.25 -1.04
Intra-day 0.25 0.04 14.74 4.54 0.74 0.07 9.63 2.36 2.42 0.15 6.26 8.71 13.57 1.42 10.49 8.60
CV - Coefficient  of Variation; SD – Standard Deviation; LQC – Low Quality Control samples; MQC – Medium Low Quality Control samples; HQC – High Low Quality Control samples







A(n=6)             B(n=6)          C(n=6)
Mean peak Area 
ratio
    B2               C2
ME (%) 
B/A




Analysis RE (%) 
C2/B2
11.3 152234 155868 149635 0.39 0.41 102.4 96.0 98.3 105.1
150 1896308 1842656 1891241 6.3 5.83 97.2 102.6 99.7 92.5Plasma
750 8873971 8749945 8816279 31.47 28.41 98.6 100.8 99.3 90.3
0.72 6171 6684 5801 0.40 0.44 108.3 86.8 94.0 109.8
2.25 27740 28987 31494 1.30 1.41 104.5 108.6 113.5 108.5CSF
12.5 163512 149438 143166 12.72 11.55 91.4 95.8 87.6 90.8
ME (%) - % Matrix effect; Ext RE (%) - % Extraction Recovery Efficiency; PE (%) - % Process Efficiency; Analysis RE (%) - % Analysis Recovery Efficiency; L – Low, M - Medium, H - High
































































Table 4. Stability data for CVC under different storage conditions
Stability 
measured QC Precision (%CV) Accuracy (%)
LQC 10.08 -9.69
MQC 5.16 1.22Benchtop (6h)
HQC 10.81 -1.09
LQC 6.56 -3.47
MQC 1.41 7.61Heat inactivation
HQC 4.24 0.679
LQC 1.79 -8.875






(48h) HQC 8.35 1.55
QC – Quality Control samples; LQC – Low Quality Control samples; MQC – Medium Low Quality Control samples;
HQC – High Low Quality Control samples
Table 5. Individual subject blood and cerebrospinal fluid concentration at week 8
Cenicriviroc concentration Subject 1 Subject 2 Subject 3 Subject 4
CSF, ng/mL 0.82 0.40 (<LLQ) (<LLQ)
Plasma, ng/mL 718.60 211.06 411.93 70.50














Cenicriviroc dose 150 mg 50 mg 150 mg 150 mg

































































Figure 1. Chromatograms of cenicriviroc and cenicriviroc-d7 in CSF 
171110_ACCESS_CVC_CSF_PA5_EC_005_171110101409 - m/z= 574.30  SM: 15 RT: 0.00 - 5.00 NL: 8.11E1
F: + c ESI SRM ms2 697.300 [354.195-354.205, 574.295-574.305]





































3.222.891.66 3.38 4.624.454.000.25 0.67 4.834.160.94
a)
171110_ACCESS_CVC_CSF_PA5_EC_007 - m/z= 574.30  SM: 15 RT: 0.00 - 5.00 NL: 6.16E2
F: + c ESI SRM ms2 697.300 [354.195-354.205, 574.295-574.305]

































2.741.91 2.551.40 3.261.700.31 0.69 0.89 1.09 3.72 4.670.12 3.943.503.07 4.17 4.36
b)
































































ASY047_171110_ACCESS_BC93101A_108B_EC_036 - m/z= 574.30  SM: 15 RT: 0.00 - 5.00 NL: 8.54E2
F: + c ESI SRM ms2 697.300 [354.195-354.205, 574.295-574.305]

































2.411.63 2.722.561.88 3.641.40 4.333.31 4.913.893.110.30 4.10 4.690.960.10 1.170.58
c)
171110_ACCESS_CVC_CSF_PA5_EC_020 - m/z= 574.20  SM: 15 RT: 0.01 - 5.00 NL: 2.66E3
F: + c ESI SRM ms2 704.400 [354.095-354.105, 574.295-574.305]

































2.48 2.731.57 2.91 3.531.840.25 3.83 4.754.391.41 4.584.143.190.860.52 1.07 3.35
d)
































































Figure 2. Chromatograms of cenicriviroc and cenicriviroc-d7 in Plasma 
ASY047_171101_ACCESS_BC93001A_8B_EC_001 - m/z= 574.30  SM: 15 RT: 0.01 - 5.00 NL: 3.01E1
F: + c ESI SRM ms2 697.300 [354.195-354.205, 574.295-574.305]








































4.720.34 4.21 4.480.55 0.78
e)
ASY047_171101_ACCESS_BC93001A_8B_EC_003 - m/z= 574.30  SM: 15 RT: 0.00 - 5.00 NL: 1.31E4
F: + c ESI SRM ms2 697.300 [354.195-354.205, 574.295-574.305]


































1.61 2.781.41 3.201.21 2.971.87 4.843.37 3.57 4.411.02 3.810.630.32 4.12
f)
































































ASY047_171101_ACCESS_BC93001A_8B_EC_030 - m/z= 574.30  SM: 15 RT: 0.00 - 5.00 NL: 1.85E6
F: + c ESI SRM ms2 697.300 [354.195-354.205, 574.295-574.305]


































2.86 3.751.48 3.541.20 3.171.02 1.83 4.274.04 4.904.710.44 0.65 4.490.22 0.85
g)
ASY047_171101_ACCESS_BC93001A_8B_EC_039 - m/z= 574.20  SM: 15 RT: 0.00 - 5.00 NL: 8.33E4
F: + c ESI SRM ms2 704.400 [354.095-354.105, 574.295-574.305]


































2.801.68 3.141.03 4.583.38 3.641.19 1.45 3.98 4.860.760.20 0.48 4.404.153.81
h)
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